Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study

Abstract

Purpose To compare the efficacies of mirabegron 50 mg addition after alpha-adrenoreceptor blocker in terms of reducing storage symptoms in patients with BPH. Materials and Methods Fifty-eight patients that had been taking alpha-adrenoreceptor blocker for more than 8 weeks, but had an OABSS of greater than 3 points, were initially enrolled. One group added any alpha-adrenoreceptor blocker with mirabegron 50 mg (n=39; the mirabegron group) and the other group received alpha-adrenoreceptor blocker only (n=19; the control group) for 8 weeks. Results In the control group, mean total IPSS decreased from 15.7 to 13.1 (p=0.298) and in mirabegron group, mean total IPSS decreased from 19.4 to 16.5 (p=0.024). Mean storage symptom scores reduced in the control and mirabegron groups from 8.5 to 7.9 (p=0.584) and from 9.1 to 7.6 (p=0.015), respectively, and mean QoL scores from 3.7 to 3.1 (p=0.052) and 3.6 to 3.2 (p=0.027), respectively. Mean overall OABSS in the control and mirabegron groups reduced from 8.4 to 7.2 (p=0.173) and from 8.8 to 7.3, respectively (p=0.005); mean OABSS Q3 from 3.6 to 2.9 (p=0.073) and from 3.5 to 2.7 (p=0.002), respectively; and mean OABSS Q4 from 2.4 to 2.0 (p=0.306) and from 2.7 to 2.0 (p=0.016), respectively. The change of mean Qmax and PVR was insignificant in 2 groups. Conclusions IPSS total scores, storage symptom scores, QoL, overall OABSS, OABSS Q3 and Q4 were more improved significantly by alpha-adrenoreceptor blocker with mirabegron 50 mg in BPH patients with persistent overactive symptoms. Mirabegron 50 mg addition is considered to patients with persistent storage symptoms after alpha-adrenoreceptor blocker.

Safety and efficacy of an α1‐blocker plus mirabegron compared with an α1‐blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta‐analysis

“…Of these, 1015 records were excluded, and 24 were identified that could be included in the meta‐analysis (Table 1). 15,16,19–40 Of these 24 records, 20 investigated the use of an α 1 ‐blocker plus antimuscarinic and four analyzed the use of an α 1 ‐blocker plus mirabegron. One of the excluded records was from a study that had directly compared an α 1 ‐blocker plus antimuscarinic with an α 1 ‐blocker plus mirabegron 41 .…”

“…Variations in the study design between our meta‐analysis and this previous investigation may explain why different results were achieved in the two studies. For example, our current study also included an investigation by Kwon et al, which analyzed the use of an α 1 ‐blocker plus mirabegron with an α 1 ‐blocker 38 . This study was published after this previous meta‐analysis 38,48 …”

“…For example, our current study also included an investigation by Kwon et al, which analyzed the use of an α 1 -blocker plus mirabegron with an α 1blocker. 38 This study was published after this previous meta-analysis. 38,48 This study involved completing a comprehensive meta-analysis, but our investigation does have some limitations.…”

“…For example, our current study also included an investigation by Kwon et al, which analyzed the use of an α 1 ‐blocker plus mirabegron with an α 1 ‐blocker 38 . This study was published after this previous meta‐analysis 38,48 …”

The relevance of studying the state of blood circulation of the neurogenic bladder in children

“…Альфаадреноблокаторы показали свою эффективность в различных аспектах коррекции нейрогенных расстройств мочевого пузыря. Так, в определенных клинических ситуациях терапия адреноблокаторами может привести к таким результатам, как уменьшение степени пузырномочеточникового рефлюкса (ПМР), улучшение со стороны императивного недержания, более редкие обострения инфекций мочевыводящих путей, выраженное улучшение уродинамических показателей, уменьшение или устранение остаточной мочи [21][22][23][24].…”